Skip to main content
. 2019 Oct 11;10:4635. doi: 10.1038/s41467-019-12554-2

Fig. 5.

Fig. 5

Brain localization of NLCs and NLC-siRNA complexes and demonstration of pharmacological activity. a, b Fluorescent microscopy images of brain cerebral sections at 4 h after the administration of FAM-CGY NLCs (final concentration of 10 μM) (a) and FAM-CGY/Cy5-siRNA complexes (FAM-CGY = 10 μM, Cy5-siRNA = 48 nM) (b), respectively. Astrocytes, neurons and microglia were labelled with anti-GFAP, anti-Tuj1, anti-Iba1 antibodies, respectively and visualised with a secondary fluorescent antibody (Cy-3 channel). Inserts represent enlarged sections. Arrows indicate FAM-CGY NLC and FAM-CGY/Cy5-siRNA complexes. Cy3-Channel: astrocytes or neurons or microglial cells; FAM-Channel: FAM-CGY NLCs, Cy5-Channel: Cy5-siRNA. Cell nuclei are stained with DAPI. Scale bar = 40 μm. The images show NLC localization to neurons and microglial cells, but not astrocytes. c Western blot demonstration of suppression of β-secretase 1 (BACE1) expression in hippocampus following a single intravenous injection of FAM-CGY/BACE1 siRNA complexes. Silencing was compared with FAM-CGY/siControl injection. BACE1-specific siRNA alone or delivered with the FAM-CGY scrambled peptide 1 (FAM-CGY SP) did not induce silencing. BACE1 expression was measured 48 h after administration. The results represent mean values of three separate experiments ± s.d. *p < 0.05, non-paired two-sided student t-test compared with respective siControl (control siRNA). Source data are available in the Source Data file